AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial. Firmonertinib did not significantly improve progression-free survival compared with chemotherapy. The 240 mg dose produced a 60% confirmed response rate, compared to 33% for chemotherapy. The company continues to test the drug in a separate Phase 3 trial … Read more